LONDON \u2014 European markets opened higher on Tuesday, paring the previous session’s losses. <\/p>\n
The pan-European\u00a0Stoxx 600<\/a> advanced 0.3% by 8:30 a.m. in London (4:30 a.m. ET), hitting a fresh high of 588.42 points just days after surpassing its previous record. <\/p>\n The benchmark ended the previous session 0.1% lower on Monday. Still, it has risen 14% higher this year and, with a week to go, it looks on track for its third consecutive year of gains. <\/p>\n Investors will be watching Novo Nordisk stock after the Wegovy-maker gained FDA approval for the first-ever GLP-1 pill<\/a>, giving the Danish firm a head start over U.S. rival Eli Lilly<\/a>. Novo Nordisk’s share price was 6% higher<\/a> in the first moments of trade on Tuesday.<\/p>\n Shares in French biotech\u00a0Abivax<\/a>\u00a0extended gains into a second day, advancing 3.6%. The company \u2014\u00a0one of Europe’s best-performing stocks<\/a>\u00a0this year \u2014 popped 15.4% on Monday.<\/p>\n Danish renewables giant\u00a0Orsted<\/a>\u00a0shed 13% on Monday after the U.S. Department of the Interior said it was\u00a0suspending leases<\/a>\u00a0on five offshore wind projects already under construction. Orsted successfully challenged the Trump administration<\/a>‘s stop-order on the nearly-completed Revolution Wind\u00a0project off Rhode Island when it was halted earlier this year. Its shares moved 1.7% lower in early dealmaking but were last seen just below the flatline.<\/p>\n